CN102770135A - 眼内压降低作用持续时间长的α-2肾上腺素能激动剂 - Google Patents

眼内压降低作用持续时间长的α-2肾上腺素能激动剂 Download PDF

Info

Publication number
CN102770135A
CN102770135A CN2011800111530A CN201180011153A CN102770135A CN 102770135 A CN102770135 A CN 102770135A CN 2011800111530 A CN2011800111530 A CN 2011800111530A CN 201180011153 A CN201180011153 A CN 201180011153A CN 102770135 A CN102770135 A CN 102770135A
Authority
CN
China
Prior art keywords
intraocular pressure
bromo
hours
weight
imidazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800111530A
Other languages
English (en)
Chinese (zh)
Inventor
J·E·多纳罗
D·W·吉尔
M·I·蒂巴斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44169074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102770135(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN102770135A publication Critical patent/CN102770135A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800111530A 2010-01-21 2011-01-21 眼内压降低作用持续时间长的α-2肾上腺素能激动剂 Pending CN102770135A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29691210P 2010-01-21 2010-01-21
US61/296,912 2010-01-21
PCT/US2011/022001 WO2011091225A2 (en) 2010-01-21 2011-01-21 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect

Publications (1)

Publication Number Publication Date
CN102770135A true CN102770135A (zh) 2012-11-07

Family

ID=44169074

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800111530A Pending CN102770135A (zh) 2010-01-21 2011-01-21 眼内压降低作用持续时间长的α-2肾上腺素能激动剂

Country Status (17)

Country Link
US (1) US9889088B2 (https=)
EP (1) EP2525793B1 (https=)
JP (3) JP2013518051A (https=)
KR (1) KR20120125305A (https=)
CN (1) CN102770135A (https=)
AU (1) AU2011207301A1 (https=)
BR (1) BR112012018154A2 (https=)
CA (1) CA2787573A1 (https=)
CL (1) CL2012002038A1 (https=)
CO (1) CO6592108A2 (https=)
IL (1) IL221030A0 (https=)
MX (1) MX2012008516A (https=)
RU (1) RU2012134065A (https=)
SG (1) SG182637A1 (https=)
TW (1) TW201141477A (https=)
WO (1) WO2011091225A2 (https=)
ZA (1) ZA201205470B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188700A (zh) * 2013-03-14 2015-12-23 阿勒根公司 通过玻璃体内和前房内途径用于治疗眼内压和眼部疾病的α-2肾上腺素能激动剂

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
US20130046003A1 (en) * 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
TWI699205B (zh) * 2014-12-12 2020-07-21 日商興和股份有限公司 用於預防或治療青光眼之藥物療法
EP3647420B1 (en) 2017-06-27 2023-08-23 The University Of Tokyo Probe and method for detecting transcript resulting from fusion gene and/or exon skipping
US11077053B2 (en) 2018-08-21 2021-08-03 Allergan, Inc. Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
PT4236932T (pt) * 2020-11-02 2026-02-23 Visus Therapeutics Inc Composto degradante num medicamento
WO2023086878A1 (en) * 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004270A1 (en) * 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Novel benzimidazole derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6495583B1 (en) * 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP2009500409A (ja) * 2005-06-29 2009-01-08 アラーガン、インコーポレイテッド 痛みを処置するためのα２アドレナリン作動剤
JP2009525970A (ja) * 2006-02-06 2009-07-16 ニコックス エス エイ α２−アドレナリン受容体アゴニストとしてのアプラクロニジンおよびブリモドニジンのニトロオキシ含有誘導体
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004270A1 (en) * 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Novel benzimidazole derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188700A (zh) * 2013-03-14 2015-12-23 阿勒根公司 通过玻璃体内和前房内途径用于治疗眼内压和眼部疾病的α-2肾上腺素能激动剂

Also Published As

Publication number Publication date
MX2012008516A (es) 2012-10-15
JP2017125074A (ja) 2017-07-20
EP2525793B1 (en) 2018-09-05
US9889088B2 (en) 2018-02-13
ZA201205470B (en) 2013-05-29
CO6592108A2 (es) 2013-01-02
RU2012134065A (ru) 2014-02-27
BR112012018154A2 (pt) 2016-04-05
CL2012002038A1 (es) 2012-11-16
AU2011207301A1 (en) 2012-08-09
JP2013518051A (ja) 2013-05-20
SG182637A1 (en) 2012-08-30
IL221030A0 (en) 2012-09-24
CA2787573A1 (en) 2011-07-28
TW201141477A (en) 2011-12-01
JP6466504B2 (ja) 2019-02-06
US20110178145A1 (en) 2011-07-21
WO2011091225A3 (en) 2012-05-18
EP2525793A2 (en) 2012-11-28
JP2016026206A (ja) 2016-02-12
KR20120125305A (ko) 2012-11-14
WO2011091225A2 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
JP6466504B2 (ja) 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト
US20210405280A1 (en) Combination of brimonidine and timolol for topical ophthalmic use
EP3954362A1 (en) Method of increasing bioavailability and/or prolonging ophthalmic action of a drug
WO2010059894A1 (en) Ocular formulations of norketotifen
CN103747786A (zh) 比马前列素和溴莫尼定的固定剂量组合
WO2017066052A1 (en) Formulations and methods for treating high intraocular pressure
CN109966245A (zh) 一种酒石酸溴莫尼定结冷胶型原位凝胶滴眼液及制备方法
EP2765988B9 (en) Ocular composition containing bromfenac with increased bioavailability
JP2011144111A (ja) 軸性近視の予防または治療剤
KR102633606B1 (ko) 활성 성분으로서 티오트로피움을 포함하는, 근시 예방, 근시 치료, 및/또는 근시 진행 예방을 위한 제제
US20140275197A1 (en) Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
EP0647445A1 (en) Composition for prophylaxis and treatment of myopia
EP4230193A1 (en) Ophthalmic pharmaceutical composition
WO2002040028A1 (fr) Gouttes pour les yeux en gel antibacterien
CN104721130B (zh) 一种布林佐胺包合物眼用制剂及其制备方法
US20130210876A1 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
JPH10500130A (ja) テラゾシンを含有する緑内障治療用医薬組成物
KR20100032018A (ko) 항히스타민제를 포함하는 점안용 조성물
JP2026505378A (ja) 視覚を改善するためのα２アドレナリン作動薬
WO2023048174A1 (ja) 角膜疾患治療剤
HK40016534A (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121107